Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Aug 6, 2020 at 5:00 PM EDT
May 27, 2020
May 19, 2020 at 3:50 PM EDT